IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s Why

IPSEN (OTCMKTS:IPSEY)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $48.52, but opened at $45.7620. IPSEN shares last traded at $45.7620, with a volume of 539 shares.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IPSEY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. HC Wainwright restated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Zacks Research raised IPSEN to a “hold” rating in a report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, IPSEN currently has a consensus rating of “Hold”.

IPSEN Trading Down 4.1%

The stock’s 50-day moving average is $47.10 and its 200 day moving average is $44.55.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).